AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase III WAYPOINT study for their co-developed drug Tezspire (tezepelumab). Tezspire is a thymic stromal lymphopoietin (TSLP) – targeted monoclonal antibody (mAb) that has been approved for severe asthma in over 60 countries worldwide.
Study Results
The WAYPOINT study was designed to assess the efficacy and safety of Tezspire in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The results showed that the drug significantly reduced nasal polyp severity, with a Nasal Polyp Score (NPS) reduction of -2.065 and nasal congestion reduction of -1.028 at week 52 compared to placebo. Additionally, Tezspire significantly reduced the need for subsequent nasal polyp surgery by 98% and systemic corticosteroid treatment by 88%.
Future Prospects
AstraZeneca and Amgen are also testing Tezspire in clinical studies for chronic obstructive pulmonary disease (COPD) and other indications. They have submitted market filings for the drug in CRSwNP to multiple regulatory bodies, indicating the potential for further approvals and expanded use of Tezspire in the treatment of respiratory conditions.-Fineline Info & Tech
Leave a Reply